Healthcare IT Today
JANUARY 23, 2024
Drug population and drug protocol fit account for nearly 75% of these failures. By simulating trials at scale, QuantHealth’s platform can lower risks, expedite, and optimize drug development. Petra Jantzer, Ph.D.,
Digital Health Global
FEBRUARY 19, 2024
Centered on digital biomarker and safety monitoring algorithm development, with a specific emphasis on cytokine release syndrome (CRS) detection, the oncology programs harness cutting-edge data science and technology to elevate remote data collection, patient monitoring, and safety protocols. Full press release here
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Mobi Health News
DECEMBER 26, 2024
The report highlights America's leadership in its approach to responsible AI innovation while at the same time considering guardrails that may be applicable to safeguard the nation against current and emerging threats. When used properly, uses of AI could lead to increased efficiency, better patient care and better outcomes.
Healthcare IT Today
JANUARY 3, 2025
AI capabilities will become a critical differentiator, with companies that successfully implement AI solutions gaining significant advantages in drug discovery and development speed, cost reduction, and market intelligence. It’s not just a trend, but a reality we fully expect will accelerate in the coming year.
Healthcare IT Today
JANUARY 4, 2025
Amid a history of high-profile breaches, more organizations are taking a proactive approach to cybersecurity and having discussions at a leadership level. On the pharma front, expect an emphasis on AI for inventory management and targeted drug development , plus a shake-up in the market for weight-loss drugs.
Digital Health Global
MARCH 2, 2023
As part of the partnership, SSI will expand Koneksa’s medical strategy division, especially in translational and clinical drug development. Koneksa clients gain access to a team of PhDs and MDs at SSI with expertise in drug development.
Digital Health Global
NOVEMBER 12, 2024
23andMe tried to monetize its extensive genetic database by collaborating with pharmaceutical companies for drug research. While promising, drug development requires significant time and investment, delaying any financial returns and impacting the company’s short-term revenue.
Expert insights. Personalized for you.
117 
Let's personalize your content